4 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow Burkitt's Lymphoma: new trials by email Literature Review of Burkitt's Lymphoma trials Research Report on Burkitt's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers 19(T2)28z1xx CAR T cells - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-07-06 | 2026-08-27 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) ADCT-402 - Non-Hodgkin Lymphoma, Burkitt's Lymphoma | Phase 1 | Completed | ADC Therapeutics S.A. | 183 | 2016-03-01 | 2021-05-19 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Treg cells, CD3+ Teff cells, Fludarabine - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2014-01-01 | 2017-12-02 | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies HSC835 - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 27 | 2012-01-09 | 2020-12-30 |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Alisertib (MLN8237), Rituximab, Vincristine - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 45 | 2011-08-09 | 2018-03-27 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 4 | 2007-01-01 | 2025-11-05 |
| Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Clofarabine, Cyclophosphamide - Burkitt's Lymphoma, Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 51 | 2006-03-01 | 2013-03-12 |
Burkitt Lymphoma (7) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Mantle-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Waldenstrom Macroglobulinemia (2) · Anemia, Refractory, with Excess of Blasts (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia (1)
DNA Virus Infections (7) · Epstein-Barr Virus Infections (7) · Hemic and Lymphatic Diseases (7) · Herpesviridae Infections (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Infections (7) · Lymphatic Diseases (7) · Lymphoma, B-Cell (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Tumor Virus Infections (7) · Virus Diseases (7) · Hematologic Diseases (6)
Cyclophosphamide (2) · Clofarabine (1) · Cord Blood Stem Cell Transplantation (1) · Cytarabine (1) · Etoposide (1) · MLN 8237 (1) · Rituximab (1) · Sirolimus (1) · Vincristine (1) · Whole-Body Irradiation (1) · fludarabine (1) · fludarabine phosphate (1) · loncastuximab tesirine (1)
ADC Therapeutics S.A. (1) · Abramson Cancer Center at Penn Medicine (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · Millennium Pharmaceuticals, Inc. (1) · Novartis Pharmaceuticals (1)
United States (7) · Italy (2) · United Kingdom (2) · Spain (1)
Claudio Brunstein, MD, PhD (1) · Jae Park, MD (1) · Selina Luger, MD (1) · Stefan Faderl, MD (1)
PMID 30082475, PMID 31685491, PMID 33211842, PMID 34515338, PMID 34893942, PMID 39883889
2016 (1)